Sugi Predict

Sugi Predict / Compounds / SCHEMBL2881001

SCHEMBL2881001

SCHEMBL2881001

O=C(O)c1ncnc2ccsc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 7/20 0.57
▸ ADORA2B P29275 2/20 0.57
▸ AXL P30530 1/20 0.52
▸ MKNK1 Q9BUB5 1/20 0.52
▸ MKNK2 Q9HBH9 1/20 0.52
▸ CAMKK1 Q8N5S9 1/20 0.44
▸ CAMKK2 Q96RR4 1/20 0.44
▸ PDE4A P27815 1/20 0.43
▸ PDE4B Q07343 1/20 0.43
▸ PDE4C Q08493 1/20 0.43
▸ PDE4D Q08499 1/20 0.43
▸ PDE3B Q13370 1/20 0.43
▸ PDE3A Q14432 1/20 0.43
▸ PDPK1 O15530 1/20 0.41
▸ PARP1 P09874 1/20 0.41
▸ HTR2C P28335 1/20 0.41
▸ ADORA1 P30542 4/20 0.40
▸ PIP4K2C Q8TBX8 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27726470 0.84 ADORA2A (0.45) ADORA2AADORA2BAXLMKNK1MKNK2
SCHEMBL29494878 0.84 ADORA2A (0.56) ADORA2AADORA2BAXLMKNK1MKNK2
SCHEMBL3661823 0.84 ADORA2A (0.56) ADORA2AADORA2BAXLMKNK1MKNK2
SCHEMBL14074698 0.84 ADORA2A (0.60) ADORA2AADORA2BAXLMKNK1MKNK2
SCHEMBL14074693 0.80 ADORA2A (0.56) ADORA2AADORA2BAXLMKNK1MKNK2
SCHEMBL27726474 0.79 TSHR (0.51) ADORA2AADORA2BMEN1KMT2A
SCHEMBL30095652 0.78 ADORA2A (0.54) ADORA2AADORA2BAXLMKNK1MKNK2
SCHEMBL28762328 0.74 ADORA2A (0.47) ADORA2AADORA2BAXLMKNK1MKNK2
Trifluoroacetic Acid SCHEMBL31745019 0.74 ADORA2A (0.44) ADORA2AADORA2BAXLMKNK1MKNK2
SCHEMBL5334636 0.73 EGFR (0.55) PDE4APDE4BPDE4CPDE4DPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INT (DE) 2026-03-19 — — US disclosed
EP-2207780-B1 THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS VERNALIS R&D LTD (GB) 2013-05-15 — — EP disclosed
US-8354415-B2 Thienopyrimidine compounds and compositions VERNALIS (R&D) LTD. (GB) 2013-01-15 — — US disclosed
US-7968536-B2 Heterocyclic compounds useful as RAF kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-06-28 — — US disclosed
US-7968536-B2 Heterocyclic compounds useful as RAF kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-06-28 — — US disclosed
US-20100298349-A1 THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS VERNALIS (R&D) LTD. (GB) 2010-11-25 — — US disclosed
EP-1768984-B1 THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS SUNESIS PHARMACEUTICALS INC (US) 2010-10-20 — — EP disclosed
EP-2207780-A1 THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS Vernalis (R&D) Ltd. (GB) 2010-07-21 — — EP disclosed
US-20100179123-A1 THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2010-07-15 — — US disclosed
US-7601725-B2 Thienopyrimidines useful as Aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2009-10-13 — — US disclosed
WO-2009037468-A1 THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS VERNALIS (R & D) LTD. (GB) 2009-03-26 — — WO disclosed
WO-2009006404-A2 HETEROCYCLIC COMPOUNDS USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2009-01-08 — — WO disclosed
US-20090005359-A1 Heterocyclic Compounds Useful as RAF Kinase Inhibitors SUNESIS PHARMACEUTICALS, INC (US) 2009-01-01 — — US disclosed
US-20090005359-A1 Heterocyclic Compounds Useful as RAF Kinase Inhibitors SUNESIS PHARMACEUTICALS, INC (US) 2009-01-01 — — US disclosed
US-20080221092-A1 Heterobicyclic metalloprotease inhibitors BLUHM HARALD 2008-09-11 — — US disclosed
US-20080221092-A1 Heterobicyclic metalloprotease inhibitors BLUHM HARALD 2008-09-11 — — US disclosed
CN-101160316-A Thienopyrimidines useful as aurora kinase inhibitors SUNESIS PHARMACEUTICALS INC (US) 2008-04-09 — — CN disclosed
EP-1768984-A1 THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS Sunesis Pharmaceuticals, Inc. (US) 2007-04-04 — — EP disclosed
WO-2006036266-A1 THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2006-04-06 — — WO disclosed
US-20060035908-A1 Thienopyrimidines useful as Aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. 2006-02-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298349-A1 THIENOPYRIMIDINE COMPOUNDS AND COMPOSITIONS ADORA2B, CYP2B6, RRM2B ADORA2A 51/4885ADORA2B 1/4885AXL 1633/4885
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 CD38, CD22, CD79B ADORA2A 847/4885ADORA2B 754/4885AXL 1446/4885
US-20100179123-A1 THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS AURKA, AURKB, AURKC ADORA2A 1602/4885ADORA2B 1952/4885AXL 796/4885
US-20090005359-A1 Heterocyclic Compounds Useful as RAF Kinase Inhibitors BRAF, RAF1, ARAF ADORA2A 3787/4885ADORA2B 4597/4885AXL 920/4885
US-20060035908-A1 Thienopyrimidines useful as Aurora kinase inhibitors AURKA, AURKB, AURKC ADORA2A 1847/4885ADORA2B 2017/4885AXL 598/4885
US-20080221092-A1 Heterobicyclic metalloprotease inhibitors MMP13, MMP3, TIMP3 ADORA2A 3168/4885ADORA2B 2346/4885AXL 4551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.